← NEUROCRINE BIOSCIENCES INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $83.3m | $254.7m | $141.7m | $112.3m | $187.1m | $340.8m | $262.9m | $251.1m | $233.0m | $713.0m | |
| Inventory, Net | — | $1.0m | $10.9m | $17.3m | $28.0m | $30.5m | $35.1m | $38.3m | $57.4m | $69.0m | |
| Assets, Current | $310.4m | $554.9m | $737.8m | $831.0m | $1.0b | $972.8m | $1.5b | $1.6b | $1.7b | $2.5b | |
| Property, Plant and Equipment, Net | $6.3m | $10.8m | $33.9m | $41.9m | $44.6m | $58.6m | $58.6m | $70.8m | $82.6m | $89.8m | |
| Goodwill | — | — | — | — | — | — | $5.4m | $5.8m | $5.7m | — | |
| Intangible Assets, Net (Excluding Goodwill) | — | — | — | — | — | — | $37.2m | $35.5m | $36.5m | — | |
| Operating Lease, Right-of-Use Asset | — | — | — | $74.4m | $82.8m | $97.2m | $87.0m | $276.5m | $509.4m | $455.4m | |
| Other Assets, Noncurrent | — | — | — | — | $3.2m | $4.4m | $25.0m | $49.6m | $15.5m | $59.5m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | — | $31.1m | $56.2m | $126.6m | $157.1m | $185.5m | $350.0m | — | $479.1m | $686.8m | |
| Accrued Liabilities, Current | $21.1m | — | — | — | — | — | — | — | — | — | |
| Assets | $365.1m | $817.6m | $993.2m | $1.3b | $1.7b | $2.1b | $2.4b | $3.3b | $3.7b | $4.6b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $8.3m | $10.3m | $16.5m | $17.4m | $32.0m | $40.6m | $56.0m | |
| Accounts Payable, Current | $5.1m | $5.6m | $13.8m | — | — | — | — | — | — | — | |
| Operating Lease, Liability, Noncurrent | — | — | — | $86.8m | $94.4m | $105.3m | $93.5m | $258.3m | $455.1m | $415.3m | |
| Deferred Revenue, Noncurrent | $10.2m | $10.2m | $10.2m | — | — | — | — | — | — | — | |
| Liabilities, Current | $30.4m | $54.4m | $88.2m | $565.3m | $186.5m | $245.8m | $537.7m | $654.8m | $507.7m | $743.4m | |
| Other Liabilities, Noncurrent | $113k | $0 | — | $17.1m | $9.7m | $12.3m | $29.7m | $106.3m | $166.2m | $219.7m | |
| Deferred Tax Liabilities, Net | — | — | — | — | — | — | — | — | — | $12.0m | |
| Liabilities | $50.2m | $445.5m | $512.4m | $669.1m | $608.5m | $698.5m | $660.9m | $1.0b | $1.1b | $1.4b | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $87k | $89k | $91k | $92k | $100k | $100k | $100k | $100k | $100k | $100k | |
| Retained Earnings (Accumulated Deficit) | ($1.1b) | ($1.2b) | ($1.2b) | ($1.1b) | ($725.4m) | ($635.8m) | ($406.8m) | ($157.1m) | $29.2m | $447.7m | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($318k) | ($1.9m) | ($1.9m) | $1.4m | $1.8m | ($1.7m) | ($7.9m) | $7.0m | $5.8m | $13.1m | |
| Additional Paid in Capital, Common Stock | $1.4b | $1.6b | $1.7b | $1.8b | $1.8b | $2.0b | $2.1b | $2.4b | $2.6b | $2.8b | |
| Stockholders' Equity Attributable to Parent | $314.9m | $372.1m | $480.8m | $636.9m | $1.1b | $1.4b | $1.7b | $2.2b | $2.6b | $3.3b | |
| Liabilities and Equity | $365.1m | $817.6m | $993.2m | $1.3b | $1.7b | $2.1b | $2.4b | $3.3b | $3.7b | $4.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.